Ospemifene (Hormos)

Current Opinion in Investigational Drugs

Volumn 5, Issue 4, 2004, Pages 448-455

  Gennari, Luigi ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 (4 CHLORO 1,2 DIPHENYL BUT 1 ENYL)PHENOXY)ETHANOL; 2-(4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY)ETHANOL; ANTILIPEMIC AGENT; DRUG DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL; CHEMISTRY; CLINICAL TRIAL; HUMAN; OSTEOPOROSIS; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; ESTROGEN RECEPTOR MODULATORS; HUMANS; OSTEOPOROSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 3042537198     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. ICI 182,780, a new antioestrogen with clinical potential. Wakeling AE, Bowler J J STEROID BIOCHEM MOL BIOL 1992 43(1-3) 173-177
2. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC, McDonnell DP ENDOCRINOLOGY 1997 138 9 3901-3911
3. Research & development. Hormos Medical Ltd COMPANY WORLD WIDE WEB SITE 2000 July 15
4. Drug development pipepline: Fc-1271a, HM-101, HM-144. Hormos Medical Ltd COMPANY COMMUNICATION 2000 August 08
5. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Cho CH, Nuttall ME EMERGING DRUGS 2001 6 1 137-154
6. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. Taras TL, Wurz GT, DeGregorio MW J STEROID BIOCHEM MOL BIOL 2001 77 4-5 271-279
7. Pharmacokinetics of (deaminohydroxy)toremifene in humans: A new, selective estrogen-receptor modulator. DeGregorio MW, Wurz GT, Taras TL, Erkkola RU, Halonen KH, Huupponen RK EUR J CLIN PHARMACOL 2000 56 6-7 469-475
8. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW BREAST CANCER RES TREAT 2000 60 1 63-70
9. Quantitative analysis of Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy]ethanol in human plasma using high-performance liquid chromatography. Taras TL, Wurz GT, Hellmann-Blumberg U, DeGregorio MW J CHROMATOGR B 1999 724 1 163-171
10. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Voipio SK, Komi J, Halonen K, DeGregorio MW, Erkkola RU MATURITAS 2002 43 3 207-214
11. SERMs: Current status and future trends. Morello KC, Wurz GT, DeGregorio MW CRC CRIT REV ONCOL HEMATOL 2002 43 1 63-76
12. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol levels and reproductive tissues in intact and ovariectomized rats. Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z, Koskinen M, Hemminki Y, Kangas L, Vaananen HK, Harkonen P ENDOCRINOLOGY 2000 141 2 809-820
13. Comparitive effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. Qu Q, Harkonen PL, Vaananen HK J CELL BIOCHEM 1999 73 4 500-507
14. Pharmacokinetics of selective estrogen receptor modulators. Morello K, Wurz GT, DeGregorio MW CLIN PHARMACOKIN 2003 42 4 361-372
15. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM, Heikkinen J, Komi J MENOPAUSE 2003 10 5 440-447
16. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O MENOPAUSE 2003 10 5 433-439
17. Development portfolio. Hormos Medical Corp COMPANY WORLD WIDE WEB SITE 2003 November 21
18. The prevention and treatment of osteoporosis. Riggs BL, Melton LJ 3rd N ENGL J MED 1992 327 9 620-627
19. The economic and human costs of osteoporotic fracture. Barrett-Connor E AM J MED 1995 98 2A 3S-8S
20. Estrogen plus progestin and the risk of coronary heart disease. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL et al N ENGL J MED 2003 349 6 523-534
21. Breast cancer and hormonal replacement therapy. Vassilopoulou-Sellin R ANN NY ACAD SCI 2003 997 341-350
22. Scientific review of tamoxifen. Higginson J, Gelmann EP SEMIN ONCOL 1997 24 1 5-141
23. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Yang NN, Venugopalan M, Hardikar S, Glasebrook A SCIENCE 1996 273 5279 1222-1225
24. The effect of two selective estrogens raloxifene and FC1271a on osteoclast survival and resorption in vitro. Parikka V, Lehenkari P, Harkonen PL, Vaananen HK BONE 1998 23 S5-S552
25. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW CANCER CHEMOTHER PHARMACOL 1990 25 4 247-251
26. Tamoxifen therapy for breast cancer and endometrial cancer risk. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L J NATL CANCER INST 1999 91 19 1654-1662
27. Estrogen plus progestin and colorectal cancer in postmenopausal women. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL et al N ENGL J MED 2004 350 10 991-1004
28. An estrogen receptor basis for raloxifene action in bone. Bryant HU, Glasebrook AL, Yang NN, Sato M J STEROID BIOCHEM MOL BIOL 1999 69 1-6 37-44
29. GUIDELINES PRECLINICAL EVALUATION CLIN TRIALS OSTEOPOROSIS World Health Organisation, Geneva, Switzerland 1998 vi 68